Identification of somatic mutations in human prostate cancer by RNA-Seq

Gene

Volumn 519, Issue 2, 2013, Pages 343-347

  Xu, XiaoLin ^a   Zhu, KaiChang ^a   Liu, Feng ^a   Wang, Yue ^a   Shen, JianGuo ^a   Jin, Jizhong ^a   Wang, Zhong ^a   Chen, Lin ^a   Li, Jiadong ^a   Xu, Min ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Prostate cancer; RNA Seq; Somatic mutations; Transcript

Indexed keywords

TRANSCRIPTOME; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER GROWTH; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE FREQUENCY; HUMAN; HUMAN TISSUE; INDEL MUTATION; MALE; OPEN READING FRAME; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

GENE DELETION; GENE EXPRESSION PROFILING; HUMANS; INDEL MUTATION; MALE; PROSTATIC NEOPLASMS; RNA, NEOPLASM; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, RNA; TRANSCRIPTOME;

EID: 84875596464     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.01.046     Document Type: Article

References (51)

1. Agell L., et al. KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations. Mod. Pathol. 2008, 21:1470-1478.
2. Alexa A., Rahnenfuhrer J., Lengauer T. Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics 2006, 22:1600-1607.
3. An C.L., Chen D., Makridakis N.M. Systematic biochemical analysis of somatic missense mutations in DNA polymerase beta found in prostate cancer reveal alteration of enzymatic function. Hum. Mutat. 2011, 32:415-423.
4. Ashburner M., et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000, 25:25-29.
5. Bass B.L. RNA editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem. 2002, 71:817-846.
6. Cánovas A., Rincon G., Islas-Trejo A., Wickramasinghe S., Medrano J.F. SNP discovery in the bovine milk transcriptome using RNA-Seq technology. Mamm. Genome. 2010, 21:592-598.
7. Chepelev I., Wei G., Tang Q., Zhao K. Detection of single nucleotide variations in expressed exons of the human genome using RNA-Seq. Nucleic Acids Res. 2009, 37:e106.
8. Cirulli E.T., et al. Screening the human exome: a comparison of whole genome and whole transcriptome sequencing. Genome Biol. 2010, 11:R57.
9. Cloonan N., et al. Stem cell transcriptome profiling via massive-scale mRNA sequencing. Nat. Methods 2008, 5:613-619.
10. Dong J.T. Prevalent mutations in prostate cancer. J. Cell. Biochem. 2006, 97:433-447.
11. Eeles R.A., et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 2008, 40:316-321.
12. Futreal P.A., et al. A census of human cancer genes. Nat. Rev. Cancer 2004, 4:177-183.
13. Goodsell D.S. The molecular perspective: major histocompatibility complex. Oncologist 2005, 10:80-81.
14. Gottlieb B., Beitel L.K., Wu J.H., Trifiro M. The androgen receptor gene mutations database (ARDB): 2004 update. Hum. Mutat. 2004, 23:527-533.
15. Gregg C., Zhang J., Butler J.E., Haig D., Dulac C. Sex-specific parent-of-origin allelic expression in the mouse brain. Science 2010, 329:682-685.
16. Gregg C., et al. High-resolution analysis of parent-of-origin allelic expression in the mouse brain. Science 2010, 329:643-648.
17. Gudmundsson J., et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 2007, 39:631-637.
18. Gudmundsson J., et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat. Genet. 2007, 39:977-983.
19. Haiman C.A., et al. A common genetic risk factor for colorectal and prostate cancer. Nat. Genet. 2007, 39:954-956.
20. Huusko P., et al. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat. Genet. 2004, 36:979-983.
21. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
22. Ju Y.S., et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012, 22:436-445.
23. Kannan K., Wang L., Wang J., Ittmann M.M., Li W., Yen L. Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:9172-9177.
24. Kohno T., et al. KIF5B-RET fusions in lung adenocarcinoma. Nat. Med. 2012, 18:375-377.
25. Kridel R., et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012, 119:1963-1971.
26. Kumar-Sinha C., Tomlins S.A., Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 2008, 8:497-511.
27. Lam H.Y., et al. Detecting and annotating genetic variations using the HugeSeq pipeline. Nat. Biotechnol. 2012, 30:226-229.
28. Lee C.H., et al. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:929-934.
29. Li H., Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009, 25:1754-1760.
30. Li H., et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009, 25:2078-2079.
31. Lichtenstein P., et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 2000, 343:78-85.
32. Makridakis N.M., Caldas Ferraz L.F., Reichardt J.K. Genomic analysis of cancer tissue reveals that somatic mutations commonly occur in a specific motif. Hum. Mutat. 2009, 30:39-48.
33. Mortazavi A., Williams B.A., McCue K., Schaeffer L., Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 2008, 5:621-628.
34. Newmark J.R., et al. Androgen receptor gene mutations in human prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:6319-6323.
35. Robbins C.M., et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 2011, 21:47-55.
36. Rowley D.R., Dang T.D., McBride L., Gerdes M.J., Lu B., Larsen M. Beta-2 microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor beta 1 action. Cancer Res. 1995, 55:781-786.
37. Schaid D.J. The complex genetic epidemiology of prostate cancer. Hum. Mol. Genet. 2004, 13(Spec No 1):R103-R121.
38. Sun X., et al. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat. Genet. 2005, 37:407-412.
39. Taylor B.S., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
40. Thomas G., et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet. 2008, 40:310-315.
41. Tomlins S.A., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
42. Tomlins S.A., et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007, 448:595-599.
43. Tur V., et al. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. J. Biol. Chem. 2008, 283:20560-20568.
44. van der Sloot A.M., et al. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:8634-8639.
45. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
46. Wang Z., Gerstein M., Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 2009, 10:57-63.
47. Witte J.S. Multiple prostate cancer risk variants on 8q24. Nat. Genet. 2007, 39:579-580.
48. Wong O.G., et al. Plexin-B1 mutations in prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19040-19045.
49. Yeager M., et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 2007, 39:645-649.
50. Zhang L.Q., et al. RNA-seq reveals novel transcriptome of genes and their isoforms in human pulmonary microvascular endothelial cells treated with thrombin. PLoS One 2012, 7:e31229.
51. Zheng L., et al. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines. Hum. Mutat. 2006, 27:1062-1063.